616195-97-2

Upstream product

• 216257-25-9 3-chloro-5-[(triisopropylsilyl)oxy]phenyl chloride 
• 60964-09-2 2,6-dichloro-4-hydroxybenzaldehyde 
• 96-34-4 methyl chloroacetate 
• 591-35-5 3,5-dichlorophenol 
• 96-32-2 bromoacetic acid methyl ester 

Downstream Products

• 1021165-18-3 {3,5-dichloro-4-[6-(3,4-dimethylphenylcarbamoyl)-1H-benzoimidazol-2-yl]-phenoxy}-acetic acid methyl ester 
• 1137671-52-3 2-(2,6-dichloro-4-methoxycarbonylmethoxy-phenyl)-3H-benzoimidazole-5-carboxylic acid 

Relevant academic research and scientific papers

NOVEL THYROMIMETICS

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X1, X2, Q, R1, R2 and n are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS

The present invention provides oxadiazolyl- substituted benzimidazole- and idole-derivates that are useful for treating conditions or disorders associated with DGAT1 activity in animals, particularly humans.

NOVEL IMIDAZOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS

Compounds of the general formula (I) are valuable therapeutics for the treatment of cancer and cancer related diseases.

2-(2,6-dichlorophenyl)-diarylimidazoles

The invention is directed to compounds of formula (I), which are valuable therapeutics for the treatment of cancer and related diseases.